Table 1.
Differentially Expressed Genes That Show a 10-Fold Minimum Change in Expression from the Normal and Are Involved in Specific Pathways or Are Well Characterized with Functions That Can Be Linked to Tumor Development.
| Rank | Gene Symbol | Gene Description | Fold Change in Expression | Chromosome Location |
|---|---|---|---|---|
| 1 | SERPINA3 | Serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 | 80.89 | 14q32.1 |
| 2 | CHI3L1 | Chitinase 3-like 1 (cartilage glycoprotein-39) | 56.98 | 1q32.1 |
| 4 | CHAD2 (4, 11) | Chondroadherin | 43.68 | 17q21.33 |
| 6 | TIMP4 | Tissue inhibitor of metalloproteinase 4 | 41.47 | 3p25 |
| 7 | WEE11 (38) | WEE1 homolog (Schizosaccharomyces pombe) | 41.03 | 11p15.3–p15.1 |
| 11 | T1A-2 | Lung type-I cell membrane-associated glycoprotein | 35.21 | 1p36 |
| 12 | ABCC3 | ATP-binding cassette, subfamily C (CFTR/MRP), member 3 | 33.72 | 17q22 |
| 15 | IL1RAP2 (1, 47) | Interleukin 1 receptor accessory protein | 26.58 | 3q28 |
| 17 | CSPG4 | Chondroitin sulfate proteoglycan 4 (melanoma-associated) | 23.77 | 15q23 |
| 19 | AGTRL11 (32) | Angiotensin II receptor-like 1 | 22.36 | 11q12 |
| 22 | CD44 | Homo sapiens CD44 isoform RC (CD44) mRNA, complete cds | 19.88 | 11p13 |
| 24 | MYT1 | Myelin transcription factor 1 | 18.49 | 20q13.33 |
| 26 | TAZ | Transcriptional coactivator with PDZ-binding motif (TAZ) | 17.53 | 3q23–q24 |
| 31 | TIMP1 | Tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) | 16.23 | Xp11.3–p11.23 |
| 32 | HLA-DPA13 (1, 2, 32) | Major histocompatibility complex, class II, DP alpha 1 | 15.79 | 6p21.3 |
| 36 | S100A10 | S100 calcium binding protein A10 (annexin II ligand, calpactin I, light polypeptide (p11)) | 15.27 | 1q21 |
| 38 | TLR21 (14) | Toll-like receptor 2 | 14.66 | 4q32 |
| 40 | TFPI1 (12) | ESTs, weakly similar to cytokine receptor-like factor 2; cytokine receptor CRL2 precusor (Homo sapiens) | 14.09 | 2q32 |
| 44 | POSTN | Osteoblast-specific factor 2 (fasciclin I-like) | 12.60 | 13q13.1 |
| 46 | CHI3L2 | Chitinase 3-like 2 | 12.22 | 1p13.3 |
| 48 | CCL3 | Chemokine (C-C motif) ligand 3 | 11.89 | 17q11–q21 |
| 49 | MSR1 | Macrophage scavenger receptor 1 | 11.87 | 8p22 |
| 50 | SRPX | Sushi-repeat-containing protein, X chromosome | 11.29 | Xp21.1 |
| 51 | CSPG21 (2) | Chondroitin sulfate proteoglycan 2 (versican) | 10.86 | 5q14.3 |
| 56 | CD151 | CD151 antigen | 10.61 | 11p15.5 |
| -74 | FGF132 (5, 6) | Fibroblast growth factor 13 | -10.34 | Xq26.3 |
| -72 | MEF2C1 (5) | MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer factor 2C) | -10.48 | 5q14 |
| -70 | WNT10B2 (28, 46) | wingless-type MMTV integration site family, member 10B | -10.50 | 12q13 |
| -69 | NPY1R1 (32) | Neuropeptide Y receptor Y1 | -10.96 | 4q31.3–q32 |
| -67 | ATP2B21 (19) | Homo sapiens, similar to nuclear localization signals binding protein 1, clone IMAGE:4933343, mRNA | -11.22 | 3p25.3 |
| -66 | PRKCB115 (3–5, 7, 8, 10, 16–19, 22, 28, 36, 39, 41) | Protein kinase C, beta 1 | -11.24 | 16p11.2 |
| -65 | MAL | mal, T-cell differentiation protein | -11.55 | 2cen–q13 |
| -62 | CACNA2D31 (5) | Calcium channel, voltage-dependent, alpha 2/delta 3 subunit | -11.89 | 3p21.1 |
| -60 | GRIN13 (7, 19, 32) | Glutamate receptor, ionotropic, N-methyl d-aspartate 1 | -12.15 | 9q34.3 |
| -59 | HTR2A3 (10, 19, 32) | 5-Hydroxytryptamine (serotonin) receptor 2A | -12.22 | 13q14–q21 |
| -55 | SNAP251 (43) | Synaptosomal-associated protein, 25 kDa | -13.04 | 20p12–p11.2 |
| -54 | PTK2B4 (8, 16, 17, 19) | PTK2B protein tyrosine kinase 2 beta | -13.42 | 8p21.1 |
| -52 | VIP1 (32) | Vasoactive intestinal peptide | -14.27 | 6q26–q27 |
| -50 | VAMP11 (43) | Vesicle-associated membrane protein 1 (synaptobrevin 1) | -15.17 | 12p |
| -48 | NPY2 (32, 35) | Neuropeptide Y | -15.63 | 7p15.1 |
| -45 | ENPP2 | Ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin) | -17.09 | 8q24.1 |
| -44 | MBP | Myelin basic protein | -17.48 | 18q23 |
| -39 | HTR2C3 (10, 1, 32) | 5-Hydroxytryptamine (serotonin) receptor 2C | -19.23 | Xq24 |
| -37 | P2RX52 (19, 23) | Purinergic receptor P2X, ligand-gated ion channel, 5 | -19.57 | 17p13 |
| -32 | MATK2 (6, 15) | Megakaryocyte-associated tyrosine kinase | -23.75 | 19p13.3 |
| -31 | CRH2 (22, 32) | Corticotropin-releasing hormone | -24.27 | 8q13 |
| -22 | NEFH2 (25, 31) | Neurofilament, heavy polypeptide 200 kDa | -27.40 | 22q12.2 |
| -21 | ICAM5 | Intercellular adhesion molecule 5, telencephalin | -27.70 | 19p13.2 |
| -19 | EGR4 | Early growth response 4 | -28.90 | 2p13 |
| -15 | CAMK2A5 (7, 8, 19, 20, 28) | Calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha | -36.76 | 5q33.1 |
| -13 | ATP2B21 (19) | ATPase, Ca2+ transporting, plasma membrane 2 | -39.22 | 3p26–p25 |
| -11 | SST1 (32) | Somatostatin | -43.86 | 3q28 |
| -10 | ITPKA2 (3, 19) | Inositol 1,4,5-trisphosphate 3-kinase A | -49.50 | 15q14–q21 |
| -6 | GABRA51 (32) | γ-Aminobutyric acid (GABA) A receptor, alpha 5 | -101.01 | 15q11.2–q12 |
| -3 | CACNG3 1 (5) | Calcium channel, voltage-dependent, gamma subunit 3 | -136.99 | 16p12–p13.1 |
| -2 | CCK 1 (32) | Cholecystokinin | -146.63 | 3p22–p21.3 |
| -1 | FOXG1B | Forkhead box G1B | -325.73 | 14q12–q13 |